Lamotrigine (Psychiatric Use)
Brand names: Lamictal
This page covers lamotrigine in its psychiatric role, where it is used for the prevention of depressive episodes in bipolar disorder rather than primarily as an anticonvulsant.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Lamotrigine inhibits voltage-gated sodium channels and stabilises neuronal membranes, modulating release of excitatory neurotransmitters, which is thought to underpin its mood-stabilising effect.
Prescribing in practice
- Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis can occur, so the dose must be titrated slowly from a low starting dose and any rash, especially with systemic or mucosal involvement, prompts urgent review and usually withdrawal.
- Rapid escalation and interactions markedly affect risk: valproate raises lamotrigine levels (slower titration needed) while enzyme inducers and some hormonal contraceptives lower them, requiring dose adjustment.
- Counsel on hypersensitivity syndrome and the need to seek help for fever, swelling or blistering, and re-titrate from low dose if treatment has been interrupted.
Monitoring
Monitor for skin reactions and hypersensitivity, mood response and the impact of interacting drugs and any treatment interruption on dosing.
Counselling the patient
- Report any rash, blistering, mouth ulcers or fever urgently, particularly in the first weeks.
- Take exactly as titrated and never increase the dose faster than instructed.
- Tell your clinician about contraceptive changes, as these can alter the dose needed.
Evidence & guidelines
NICE bipolar disorder guidance supports lamotrigine for preventing bipolar depression, and product information emphasises slow titration to reduce serious rash risk.
Reference: NICE CG185 (Bipolar Disorder); MHRA Lamotrigine Safety Update; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- MAGGIC Heart Failure Risk Score · Heart Failure
- Lead aVR Sign for Left Main / Proximal LAD Occlusion · ECG Interpretation
- de Winter ECG Pattern for Proximal LAD Occlusion · ECG Interpretation
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- Corrected Sodium (Hyperglycaemia) · Electrolytes
- Hyponatraemia Cause Algorithm · Electrolyte Disorders
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185